Lung cancer trials in France

In France 316 Also abroad 2733

316 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Where
Clermont-Ferrand, Dijon, Paris, Pessac, Rennes, Suresnes, Toulouse, Vandoeuvre Les Nancy
Age
18 years and over
People
876 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07513376 · EU 2025-522643-18-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
Where
Avignon, Bron, Caen Cedex 5, Clermont Ferrand Cedex 1, Lyon, Montpellier Cedex 5, Quimper Cedex, Reims Cedex, Saint-Herblain, Strasbourg Cedex, Suresnes, Villejuif
Age
18 years and over
People
400 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07541170 · EU 2025-524263-21-01
Phase 3Taking people
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
Where
Avignon Cedex 9, Boulogne-Billancourt, Bron, Caen Cedex 5, Caen Cedex 9, Créteil, Dijon, Le Mans Cedex 9, Lyon, Lyon Cedex 04, Marseille, Nice Cedex 2, Paris, Pessac, Pierre-Bénite, Quimper Cedex, Rennes, Saint-Herblain, Saint-Herblain Cedex, Suresnes, Valenciennes, Villefranche Sur Saone Cedex, Villejuif
Age
18 years and over
People
356 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07566052 · EU 2025-524079-22-00
Phase 1/2Taking people
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Where
Lyon, Saint-Herblain, Toulouse Cedex 9, Villejuif
Age
12 years and over
People
840 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT05384626 · EU 2024-514266-39-00
Phase 3Taking people
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Where
Bayonne, Besancon Cedex, Boulogne-Billancourt, Brest, Caen Cedex 9, Chambéry, Créteil, La Roche Sur Yon Cedex 9, Le Mans Cedex 9, Lille, Marseille, Montpellier, Nantes Cedex 2, Nice Cedex 2, Nîmes, Orleans Cedex 2, Paris, Paris Cedex 14, Paris Cedex 20, Pessac, Poitiers, Quimper Cedex, Reims Cedex, Rennes, Rouen Cedex, Saint-Grégoire, Saint-Priest-en-Jarez, Strasbourg Cedex, Toulon Cedex 9, Toulouse, Toulouse Cedex 3, Tours Cedex 9, Villefranche sur Saône, Villejuif
Age
18 years to 100 years
People
750 worldwide
Run by
Amgen
See details and how to joinNCT05920356 · EU 2022-501863-41-00
Phase 3Taking people
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
Where
Angers, Bordeaux, Le Mans Cedex 9, Lyon, Vantoux
Age
18 years and over
People
290 worldwide
Run by
ETOP IBCSG Partners Foundation
See details and how to joinNCT06284317 · EU 2023-508773-82-00
Phase 3Taking people
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Where
Bordeaux, Brest, Bron, Creteil Cedex, Grenoble Cedex 9, Lille, Lyon, Marseille, Montpellier Cedex 5, Paris, Paris Cedex 18, Rennes Cedex 9, Saint-Herblain, Saint-Herblain Cedex, Strasbourg Cedex, Toulouse, Villejuif
Age
18 years and over
People
590 worldwide
Run by
Revolution Medicines, Inc.
See details and how to joinNCT06881784 · EU 2024-518154-16-00
No phaseTaking people
Analysis of Circulating Tumor Markers in Blood - ALCINA 5
Where
Montpellier
Age
18 years and over
People
620
Run by
Institut du Cancer de Montpellier - Val d'Aurelle
See details and how to joinNCT07060950
No phaseTaking people
Development of Clinical and Biological Database on Bronchial Cancer
Where
Montpellier
Age
18 years and over
People
750
Run by
Institut du Cancer de Montpellier - Val d'Aurelle
See details and how to joinNCT07085429
Phase 2Taking people
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Where
Bordeaux, Dijon, Lyon, Paris, Suresnes
Age
18 years and over
People
105 worldwide
Run by
Verastem, Inc.
See details and how to joinNCT07659782 · EU 2026-526472-23-00
Phase 1/2Taking people
A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
Where
Dijon, Marseille
Age
18 years and over
People
315 worldwide
Run by
Voronoi, Inc
See details and how to joinNCT07699328 · EU 2025-523122-40-00
No phaseNot yet taking people in France
PROMETHEE: A Shared Interregional Tele-Tobacco Cessation Platform Embedded Within the IMPULSION Lung Cancer Screening Program
Where
Pierre-Bénite
Age
50 years to 74 years
People
5,400
Run by
Hospices Civils de Lyon
See details and how to joinNCT07921719
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Where
Angers, Bobigny, Bron, Caen, Lyon, Montpellier, Nice, Paris, Pessac, Reims, Saint-Quentin, Strasbourg, Vannes
Age
18 years and over
People
600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06793215
Phase 3Taking people
First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.
Where
Avignon, Caen, Creil, Lille, Lyon, Nice, Nîmes, Paris, Saint-Cloud, Tarbes, Villejuif
Age
18 years and over
People
124
Run by
Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT06840782
Phase 3Taking people
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Where
Bordeaux, Brest, Grenoble Cedex 9, Lille, Marseille, Nantes Cedex 1, Paris, Paris Cedex 20, Rennes, Rouen, Toulouse, Villejuif
Age
18 years and over
People
680 worldwide
Run by
Pfizer
See details and how to joinNCT07144280 · EU 2025-521281-97-00
Phase 3Taking people
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Where
Bordeaux, Dijon, Lille, Limoges, Lyon, Marseille, Montpellier Cedex 5, Paris, Saint-Herblain, Toulouse, Villejuif
Age
18 years and over
People
850 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361497 · EU 2025-523576-23-00
Phase 1/2Taking people
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
Where
Lille, Lyon, Marseille, Saint-Herblain, Villejuif
Age
18 years and over
People
160 worldwide
Run by
TRIANA Biomedicines, Inc.
See details and how to joinNCT07491497 · EU 2025-524418-27-00
Phase 1Taking people
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
Where
Toulouse, Villejuif
Age
18 years and over
People
250 worldwide
Run by
Pfizer
See details and how to joinNCT07519655
Phase 1/2Taking people
A 2-part Phase 1/2 Open-label Trial on ODM-212
Where
Bordeaux, Marseille, Poitiers, Villejuif
Age
18 years and over
People
229 worldwide
Run by
Orion Corporation, Orion Pharma
See details and how to joinNCT07563738
Phase 3Taking people
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Where
Avignon Cedex 9, Bron, Lille, Lyon, Nancy, Nice Cedex 2, Paris, Pessac, Poitiers, Reims, Rennes Cedex 9, Saint-Herblain Cedex, Strasbourg Cedex, Suresnes, Toulon, Toulouse, Vantoux, Villejuif
Age
18 years and over
People
1,264 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06119581 · EU 2023-503412-33-00
Phase 1Taking people
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Where
Lyon, Saint-Herblain Cedex, Toulouse Cedex 9
Age
18 years and over
People
575 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06400472 · EU 2024-511238-11-00
Phase 3Taking people
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Bordeaux, Brest, Créteil, La Tronche, Lille, Limoges, Montpellier Cedex 5, Mulhouse, Nantes, Nice Cedex 2, Paris, Pierre-Bénite, Saint-Herblain Cedex, Suresnes, Villejuif
Age
18 years and over
People
444 worldwide
Run by
Bayer
See details and how to joinNCT06452277 · EU 2024-511319-91-00
Phase 1Taking people
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Where
Villejuif
Age
18 years and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00
Phase 3Taking people
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Where
Bobigny, Bron, La Tronche, Lyon Cedex08, Marseille, Nice, Paris, Pessac, Poitiers, Reims, Rennes, Toulouse, Vantoux, Villejuif
Age
18 years and over
People
700 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06890598 · EU 2024-512302-25-00
Phase 2Taking people
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Where
Dijon, Paris, Pierre-Bénite, Villejuif
Age
18 years and over
People
254 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07492680